What is AdAlta?
AdAlta is a biotechnology firm dedicated to pioneering novel treatments for severe diseases. At the core of its innovation is the proprietary i-body® drug discovery platform, engineered to deliver therapeutic options where conventional antibodies have limitations. The company's focus spans next-generation protein and cell therapies, with particular emphasis on fibrotic conditions and immuno-oncology. AdAlta's lead asset, AD-214, is a first-in-class therapeutic candidate designed for fibrotic diseases and solid tumors. Furthermore, the company is advancing i-CAR-T cell therapies and i-PET imaging technologies to enhance the efficacy of cancer treatments.
How much funding has AdAlta raised?
AdAlta has raised a total of $2.1M across 1 funding round:
Other Financing Round
$325K
Other Financing Round (2025): $325K, investors not publicly disclosed
What's next for AdAlta?
The substantial late-stage funding AdAlta has attracted signals a critical phase of scaling and market penetration. This capital infusion is expected to accelerate the clinical development of AD-214 and further advance its i-CAR-T and i-PET programs. The strategic nature of the recent investment suggests strong alignment with key industry players, potentially paving the way for crucial partnerships and commercialization pathways. AdAlta's focus on unmet medical needs in fibrosis and oncology positions it for significant impact, with this latest financing providing the resources to realize that potential.
See full AdAlta company page
